Zymeworks Inc (NASDAQ:ZYME) has been given a consensus recommendation of “Hold” by the seven research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $16.00.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Scotiabank downgraded Zymeworks from an “overweight” rating to an “underweight” rating in a report on Thursday, September 7th. Barclays PLC reaffirmed an “underweight” rating and set a $8.00 price target on shares of Zymeworks in a report on Thursday, September 7th. Finally, Cormark reaffirmed a “buy” rating on shares of Zymeworks in a report on Saturday, September 30th.

Zymeworks (NASDAQ:ZYME) opened at 8.33 on Friday. The stock’s 50 day moving average is $8.42 and its 200 day moving average is $9.11. The stock’s market capitalization is $211.07 million. Zymeworks has a 12-month low of $6.25 and a 12-month high of $14.25.

Hedge funds and other institutional investors have recently modified their holdings of the stock. OxFORD Asset Management LLP acquired a new stake in shares of Zymeworks during the second quarter worth $154,000. Sentry Investments Corp. acquired a new stake in shares of Zymeworks during the second quarter worth $206,000. Barometer Capital Management Inc. acquired a new stake in shares of Zymeworks during the second quarter worth $484,000. Finally, Franklin Resources Inc. acquired a new stake in shares of Zymeworks during the second quarter worth $6,878,000.

ILLEGAL ACTIVITY WARNING: “Zymeworks Inc (ZYME) Receives Consensus Recommendation of “Hold” from Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/27/zymeworks-inc-zyme-receives-consensus-recommendation-of-hold-from-analysts.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.